The European Patent Office, answering a generic drug maker's challenge, withdrew a patent on Britain-based AstraZeneca PLC's heartburn treatment, Nexium.
AstraZeneca officials said they were disappointed with the patent office's decision, but had other patents and intellectual property measures that protected the drug in Europe, the Wall Street Journal said. The ruling involved the drug's chemical composition. The patent was due to expire in 2014.
The generic drug maker Ratiopharm International GmbH of Germany challenged the patent, which led to the EPO's decision. Ratiopharm has not indicated its plans regarding a generic form of Nexium.
Generic drug makers are challenging Nexium's patents in the United States.
AstraZeneca said Nexium's $4.6 billion in worldwide sales accounted for about a fifth of the company's third-quarter revenue.
Copyright 2006 by United Press International
Related stories:
Combo pills: Convenience vs. cost
Popping so many pills that you sometimes forget to take a medication? The drug companies think they have the answer: combination pills, which aim to treat several ailments in one medication. Indeed, dozens of combo pills are in the works to combat a range of ailments, from asthma and heart disease to arthritis and severe heartburn, by merging at least two medications into one.
Old drugs need 'repurposing' for new uses, physician says
Overly restrictive intellectual property laws devalue the "repurposing" of existing medications for new uses, slowing their availability as life-saving treatments, a Portland researcher contends.
Government's reliance on free market economics makes essential drug prices too high for the poor
Research in Malaysia, published in the latest
PLoS Medicine, has established that drugs considered essential for adequate health care are often priced beyond the reach of the poorer members of society. It would cost, for example, three days wages for a low-paid government worker to buy a month’s supply of a commonly prescribed stomach ulcer pill.
Generics controversy issue widens
A dispute between the U.S. Justice Department and Federal Trade Commission over generic drugs is reportedly widening with implications for the drug firms.
Patent fight in India centers on AIDS drug
A patent application covering tenofovir, a major AIDS drug, has started a major patent fight in India.
Impeding U.S. generic drug use criticized
Moves by branded drug companies to slow the spread of U.S. generic drugs has been criticized by a pharmacy benefit managers' organization.
AIDS drug offered free to the Third World
The Bristol-Myers Squibb Co. has agreed to license its AIDS drug Reyataz free of charge to two Third World generic drug manufacturers.
New platinum-phosphate compounds kill ovarian cancer cells
A new class of compounds called phosphaplatins can effectively kill ovarian, testicular, head and neck cancer cells with potentially less toxicity than conventional drugs, according to a new study published this week in the journal
Proceedings of the National Academy of Sciences.